Essential Partners’s Aktis Oncology AKTS Stock Holding History

Essential Partners’s Portfolio AKTS Stock Details AKTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$78	Hold	4	–	–	﹤0.01%	2719
2026 Q2	$129	Buy	+4	New	+$82	﹤0.01%	2715

Other funds holding AKTS

MCP

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Essential Partners's AKTS Position: Q3 2026 in Review

Essential Partners held its Aktis Oncology (AKTS) position steady in Q3 2026 at 4 shares worth $78. The position accounts for ﹤0.01% of the portfolio, ranked #2719.

Essential Partners first reported a position in AKTS in Q2 2026 and has held it in 2 quarters since. The position peaked at $129 in Q2 2026. 6 funds tracked by Wall St. Rank hold AKTS as of Q3 2026.

Essential Partners held 4 shares of Aktis Oncology worth $78 as of Q3 2026.
Essential Partners left its Aktis Oncology share count unchanged in Q3 2026.
Aktis Oncology made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2719 holding.
Essential Partners first reported a position in Aktis Oncology in Q2 2026 and has held it in 2 quarters since.
Essential Partners's Aktis Oncology position peaked at $129 in Q2 2026.
6 funds tracked by Wall St. Rank held Aktis Oncology as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.